These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11858979)

  • 21. Compliance to the prescribed dose and overall treatment time in five randomized clinical trials of altered fractionation in radiotherapy for head-and-neck carcinomas.
    Khalil AA; Bentzen SM; Bernier J; Saunders MI; Horiot JC; Van Den Bogaert W; Cummings BJ; Dische S
    Int J Radiat Oncol Biol Phys; 2003 Mar; 55(3):568-75. PubMed ID: 12573743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group.
    ; ; Bijker N; Meijnen P; Peterse JL; Bogaerts J; Van Hoorebeeck I; Julien JP; Gennaro M; Rouanet P; Avril A; Fentiman IS; Bartelink H; Rutgers EJ
    J Clin Oncol; 2006 Jul; 24(21):3381-7. PubMed ID: 16801628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The EORTC Laboratory Research Division. European Organisation for Research and Treatment of Cancer.
    Brünner N; Double J; Fichtner I; Gescher A; Newell D; Oosterhuis W; Price P
    Eur J Cancer; 2002 Mar; 38 Suppl 4():S14-8. PubMed ID: 11858958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quality assurance standards drive improvements in the profile of radiation therapy departments participating in trials of the EORTC Radiation Oncology Group.
    Grant W; Hurkmans CW; Poortmans PM; Maingon P; Monti AF; van Os MJ; Weber DC
    Radiother Oncol; 2014 Sep; 112(3):376-80. PubMed ID: 25281581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The feasibility of high-dose multiple daily fractionation and its combination with anoxic cell sensitizers in the treatment of head and neck cancer. A pilot study of the Radiotherapy Group of the EORTC (European Organisation for Research on Treatment of Cancer).
    Van den Bogaert W; van der Schueren E; Horiot JC; Chaplain G; Arcangeli G; Gonzalez D; Svoboda V
    Int J Radiat Oncol Biol Phys; 1982 Oct; 8(10):1649-55. PubMed ID: 7153077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Highlights and strategies of the EORTC Leukemia Group. European Organisation for Research and Treatment of Cancer.
    de Witte T; Marie JP; Suciu S; Anak O;
    Eur J Cancer; 2002 Mar; 38 Suppl 4():S94-9. PubMed ID: 11858973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health Economics Unit achievements.
    Crott R; Neymark N
    Eur J Cancer; 2002 Mar; 38 Suppl 4():S147-50. PubMed ID: 11858982
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Strategies to promote translational research within the European Organisation for Research and Treatment of Cancer (EORTC) Head and Neck Cancer Group: a report from the Translational Research Subcommittee.
    Psyrri A; Licitra L; Lacombe D; Schuuring E; Budach W; Ozsahin M; Knecht R; Vermorken JB; Langendijk JA
    Ann Oncol; 2010 Oct; 21(10):1952-1960. PubMed ID: 20305037
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501).
    Bernier J; Cooper JS; Pajak TF; van Glabbeke M; Bourhis J; Forastiere A; Ozsahin EM; Jacobs JR; Jassem J; Ang KK; Lefèbvre JL
    Head Neck; 2005 Oct; 27(10):843-50. PubMed ID: 16161069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radiation Therapy Oncology Group (RTOG) studies in head and neck cancer.
    Marcial VA; Pajak TF; Kramer S; Davis LW; Stetz J; Laramore GE; Jacobs JR; Al-Sarraf M; Brady LW
    Semin Oncol; 1988 Feb; 15(1):39-60. PubMed ID: 3278390
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The European Organisation for Research and Treatment of Cancer strategy for new drug development in brain tumors.
    Lacombe D; Brandes AA; van den Bent M
    Semin Oncol; 2003 Dec; 30(6 Suppl 19):77-80. PubMed ID: 14765392
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
    Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
    Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proctitis after external-beam radiotherapy for prostate cancer classified by Vienna Rectoscopy Score and correlated with EORTC/RTOG score for late rectal toxicity: results of a prospective multicenter study of 166 patients.
    Goldner G; Tomicek B; Becker G; Geinitz H; Wachter S; Zimmermann F; Wachter-Gerstner N; Reibenwein J; Glocker S; Bamberg M; Feldmann H; Pötzi R; Molls M; Pötter R
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):78-83. PubMed ID: 17189064
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quality assurance in medical oncology within the EORTC. European Organisation for Research and Treatment of Cancer.
    Therasse P; De Mulder PH
    Eur J Cancer; 2002 Mar; 38 Suppl 4():S152-4. PubMed ID: 11858984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Altered fractionation in radiotherapy: from radiobiological rationale to therapeutic gain.
    Marcu LG
    Cancer Treat Rev; 2010 Dec; 36(8):606-14. PubMed ID: 20494524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High conformality radiotherapy in Europe: thirty-one centres participating in the quality assurance programme of the EORTC prostate trial 22991.
    Ataman F; Poortmans P; Davis JB; Bernier J; Giraud JY; Kouloulias VE; Pierart M; Bolla M
    Eur J Cancer; 2004 Nov; 40(16):2411-6. PubMed ID: 15519513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute symptoms, not rectally administered sucralfate, predict for late radiation proctitis: longer term follow-up of a phase III trial--Trans-Tasman Radiation Oncology Group.
    O'Brien PC; Franklin CI; Poulsen MG; Joseph DJ; Spry NS; Denham JW
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):442-9. PubMed ID: 12243820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard-fractionation radiotherapy for head-and-neck squamous cell carcinomas: first report of RTOG 9003: in regard to Fu et al. IJROBP 2000;48:7-16. Actuarial estimates of late normal-tissue effects...now!
    Dubben HH; Beck-Bornholdt HP
    Int J Radiat Oncol Biol Phys; 2001 Oct; 51(2):563. PubMed ID: 11579925
    [No Abstract]   [Full Text] [Related]  

  • 39. The EORTC and drug development. European Organisation for Research and Treatment of Cancer.
    Lacombe D; Fumoleau P; Zwierzina H; Twelves C; Hakansson L; Jayson G; Lehmann F; Verweij J; ;
    Eur J Cancer; 2002 Mar; 38 Suppl 4():S19-23. PubMed ID: 11858959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Quality Assurance programme of the Radiotherapy Group of the European Organization for Research and Treatment of Cancer (EORTC): a critical appraisal of 20 years of continuous efforts.
    Kouloulias VE; Poortmans PM; Bernier J; Horiot JC; Johansson KA; Davis B; Godson F; Garavaglia G; Pierart M; van der Schueren E
    Eur J Cancer; 2003 Mar; 39(4):430-7. PubMed ID: 12751372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.